The Effect of Linagliptin in Type 2 Diabetes Patients of 75 Years of Age and Older and the Influence on the Liver and Renal Function and the Lipid Metabolism in Comparison With Patients Less Than 75 Years of Age and CKD Patients

DOI

Bibliographic Information

Other Title
  • 75歳以上の高齢2型糖尿病患者におけるリナグリプチンの効果と肝腎機能，脂質代謝への影響―75歳未満患者との比較及び腎機能低下例での検討―

Search this article

Abstract

<p>The number of elderly patients with type 2 diabetes Mellitus (T2DM) is increasing. Such patients show a high rate of renal dysfunction in connection with aging. The selection of appropriate medicines and dosage adjustment are needed to avoid serious hypoglycemia. This study aimed to evaluate the efficacy of Linagliptin, a DPP-4 inhibitor that is primarily excreted by bile. Thirty-nine T2DM patients who were 75 years of age or older and who were newly treated with Linagliptin, who were treated with Linagliptin as an add-on to conventional anti-diabetic therapy, or who were switched to Linagliptin from other DPP-4 inhibitors (i.e., Sitagliptin, or Vildagliptin), were included in the present study. The changes in their blood glucose, renal and liver function, and serum lipid levels were investigated. The patients' blood glucose and HbA1c levels of all patients improved for 3.6 months. The renal function was not affected by treatment and the patients showed no significant change in their body weight. No hypoglycemia or other side effects occurred. In conclusion, Linagliptin had beneficial effects and could be used safely in the treatment of elderly T2DM patients with functional disorders.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top